Here are Monday's biggest analyst calls: Nvidia, SpaceX, Apple, Rivian, Amazon, CrowdStrike, Broadcom & more

Wall Street analysts issued a broad mix of upgrades, downgrades and initiations across technology, consumer, financial, healthcare and other stocks. Notable calls included Morgan Stanley cutting Coinbase’s price target to $120 from $258 and lowering estimated 2027/2028 revenue by 28%/18% and EBITDA by 47%/25%; Deutsche Bank raised CrowdStrike to Buy with a $300 target, while Melius cut Nvidia’s target to $315 from $420. Other calls cited AI positioning, buybacks, earnings uncertainty and growth prospects, with no share-price reactions reported.

Analysis

Treat this as sell-side positioning, not a broad change in fundamentals: most calls offer no new operating data, so any immediate move is vulnerable to fading. The more informative signal is the split inside AI. Optimism on cloud platforms and cybersecurity coexists with warnings that AI-infrastructure multiples may stay pressured as funding backstops and capex extend through 2028. That favors selectivity over a basket of high-beta AI names: demand can grow while returns on capital and supplier valuations disappoint. Amphenol and Amazon are plausible beneficiaries if deployment remains durable, but the calls alone do not establish incremental earnings or attractive entry valuations.

The clearest near-term fundamental risk is Coinbase: the cited estimate reductions make crypto trading activity and asset prices direct earnings drivers, not merely sentiment. Verify current exchange volumes and crypto prices before positioning. Rivian’s upgrade is explicitly dependent on the R2 ramp and gross-margin improvement; execution slippage could reverse the thesis over the next 1–3 months. Over 6–18 months, Teva’s transformation and Mohawk’s buyback commitment require evidence in reported cash generation; management intent is not itself a catalyst. Apple’s earnings are an immediate binary catalyst, while the H2O America and senior-housing calls are longer-duration theses with limited evidence here. Overall, the consensus may be underweighting AI multiple risk and overweighting analyst conviction as a catalyst; avoid chasing rating changes without estimate revisions or measurable operating proof.

Key Decisions for Investors

• Do not trade the full analyst-call list as a basket. For AI exposure, favor selective, staged entries rather than chasing upgrades; reassess if supplier guidance or spending plans weaken, or if estimates rise without follow-through in cash generation.
• Coinbase: keep on a short/watch list, not an unconditional short. Confirm crypto prices and exchange trading volumes first; persistent weakness would support downside exposure, while a sustained volume recovery would falsify the downgrade thesis.
• Rivian: wait for R2 production, delivery, and gross-margin evidence before buying the upgrade. A ramp delay or failure to improve margins over the next 1–3 months would invalidate the catalyst case.
• Treat Teva and Mohawk as proof-point watches: require reported cash-flow/portfolio progress at Teva and realized buybacks without balance-sheet deterioration at Mohawk before assigning value to transformation or capital-return claims.